Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 365-376 , December 1999

Radiotherapy: the last 25 years

References 

    REFERENCES
  1. Baclesse F. Five-year results in 431 breast cancers treated solely by röntgen rays. Ann Surg. 1965;161:103–104
  2. Bataini JP, Picco C, Martin M, Calle R. Relation between time-dose and local control of operable breast cancer treated by tumorectomy and radiotherapy or by radical radiotherapy alone. Cancer. 1978;42:1045–1053
  3. Calle, R. Pilleron, J. P. Schlienger, P. Vilcoq, J. R. Conservative management of operable breast cancer. Cancer, 42
  4. Pierquin B, Owen R, Maylin C. Radical radiation therapy of breast cancer. Int J Radiat Oncol Biol Phys. 1980;6:17–24
  5. Amalric R, Santamaria F, Robert F. Radiation therapy with or without primary limited surgery for operable breast cancer. Cancer. 1982;49:80–84
  6. Sarrazin D, Lê M, Rouësse J. Conservative treatment versus mastectomy in breast cancer tumors with microscopic diameter of 20 millimeters or less. Cancer. 1984;53:1209–1213
  7. Straus K, Lichter A, Lippmann M. Results of the National Cancer Institute early breast cancer trial. Monogr Natl Cancer Inst. 1992;11:27–32
  8. Veronesi U, Saccozzi R, Del Vecchio M. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. New Engl J Med. 1981;305:6–11
  9. Fisher B, Bauer M, Margolese R. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy in the treatment of breast cancer. N Engl J Med. 1985;312:865–873
  10. Blichert-Toft M, Rose C, Andersen JA. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Monogr Natl Cancer Inst. 1992;11:19–25
  11. Van Dongen JA, Bartelink H, Fentiman IS. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer. Monogr Natl Cancer Inst. 1992;11:15–18
  12. N Engl J Med. 1995;33:1444–1455
  13. Van Tienhoven G, van Bree NAM, Mijnheer BJ, Bartelink H. Quality assurance of the EORTC trial 22881/10882. Assessment of the role of booster dose in breast conserving therapy: the dummy run. Radiother Oncol. 1991;22:290–298
  14. Evans PM, Donovan EM, Fenton N. Practical implementation of compensators in breast radiotherapy. Radiother Oncol. 1998;49:255–265
  15. Chu KC, Tarone RE, Kessler LG. Recent trends in U.S. breast cancer incidence, survival and mortality rates. J Natl Cancer Inst. 1996;88:1571–1579
  16. Nab HW, Voogd AC, Crommelin MA. Breast cancer in south-east Netherlands, 1960–89: trends in incidence and mortality. Eur J Cancer. 1993;29a:1557–1560
  17. Mazeron JJ, Crook J, Chopin D. Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium-192. Int J Radiat Oncol Biol Phys. 1980;15:1323–1330
  18. Moonen LMF, Horenblas S, van der Voet JCM, Nuyten MJC, Bartelink H. Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation. Br J Urol. 1994;74:322–327
  19. Bartelink, H. et al., Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol, 15
  20. Lefebvre JL, Chavelier D, Lubboinski B. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase 3 trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:855–856
  21. N Engl J Med. 1991;324:1685–1690
  22. Robbins KT, Vicario D, Seagran S. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994;168:419–422
  23. Robbins KT, Kumar P. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer. The Memphis experience. Int J Radiat Oncol Biol Phys. 1996;38:263–271
  24. Simon MA, Enneking WF. The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg. 1976;58a:317–327
  25. Eilber FR, Mirra JJ, Grant TT, Weisenburger T, Morton DL. IS amputation necessary for sarcomas? A seven-year experience with limb-salvage. Ann Surg. 1980;192:431–437
  26. Lindberg R. Treatment of localized soft tissue sarcomas in adults at MD Anderson Hospital and Tumor institute (1960–1981). Cancer Treat Symp. 1985;3:59–65
  27. Rosenberg SA, Tepper J, Glatstein E. The treatment of sof-tissue sarcoma of the extremities: prospective randomized evaluation of (1) limb sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305
  28. Yang JC, Chang EA, Baker AR. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203
  29. Ragaz J, Jackson SM, Le N. Ajuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Eng J Med. 1997;337:956–962
  30. Overgaard M, Hansen PS. Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–955
  31. Hellman S. Stopping metastases at their source. N Engl J Med. 1997;14:996–997
  32. Schaake Koning C, van den Bogaert W, Dalesio O. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  33. Keys HM, Bundy BN, Stehman FB. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161
  34. Rose PG, Bundy BN, Watkins E. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153
  35. Morris M, Eifel PJ, Lu J. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143
  36. Thomas GM. Improved treatment for cervical cancer – concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198–1199
  37. Carde P. Hodgkin’s lymphoma. II. Treatment and delayed morbidity. Br J Med. 1992;305:173–176
  38. Boivin JF, Hutchison GB, Lubin JH. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer. 1992;69:1241–1247
  39. Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin’s disease therapy: the EORTC experience. Ann Oncol. 1991;2:77–82
  40. Mauch PM, Canellos GP, Rosenthal DS. Reduction of fatal complications from combined modality therapy in Hodgkin’s disease. J Clin Oncol. 1985;3:501–505
  41. Mauch PM. Reduction of treatment for early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1992;22:1159–1160
  42. Tubiana M, Hayat M, Henry-Amar M. Five year results of the EORTC randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer. 1981;17:355–363
  43. Carde P, Hayat M, Cosset JM. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine and prednisone in clinical stages I and II Hodgkin’s disease: Experience of the European Organization for Research and Treatment of Cancer. NCI Monogr. 1988;6:303–310
  44. Carde P, Hagenbeek A, Hayat M. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stages Hodgkin’s disease: the H6 twin randomized trials from the EORTC Lymphoma Cooperative Group. J Clin Oncol. 1992;11:2258–2272
  45. Zittoun, R. Audebert, A. Hoerni, B. et al., Extended versus involved fields irradiation combined with MOPP chemotherapy in early stages of Hodgkin’s disease. J Clin Oncol, 3
  46. Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ C-30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  47. Bates T, Yarnold JR, Blitzer P. Bone metastases consensus statement. Int J Radiat Oncol Biol Phys. 1992;23:215–216
  48. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985;55:1468–1472
  49. Gaze MN, Kelly CG, Kerr GR. Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother Oncol. 1997;45:109–116
  50. Hoskin PJ, Price P, Easton D. A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23:74–78
  51. Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomised trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys. 1983;9:1775–1779
  52. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247–255
  53. Tong D, Gillick L and Hendrikson FR. The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893–899
  54. Br J cancer. 1991;63:265–270
  55. Bleehen NM, Girling DJ, Machin D. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer. 1992;65:934–941
  56. Ellis F. Dose time and fractionation; a clinical hypothesis. Clin Radiol. 1969;20:1–7
  57. Douglas BG, Fowler JF. The effect of multiple small doses of X-rays on skin reactions in the mouse and a basic interpretation. Radiation Research. 1976;96:603–610
  58. Thames HD, Withers HR, Peters LD, Fletcher GH. Changes in early ad late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982;8:219–226
  59. Withers HR, Thames HD, Peters LJ. Differences in the fractionation response of acutely and late-responding tissues. Progress in Radio-Oncology. 1982;II:287
  60. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981–1999
  61. Emami B, Lyman J, Brown A. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  62. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  63. Boersman, L. J. Damen, E. M. de Boer, R. W. et al., Dose-effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma. Radiother Oncol, 32
  64. Theuws JCM, Kwa SLS, Wagenaar AC. Prediction of overall pulmonary function loss in relation to the 3-D dose distribution for patients with breast cancere and malignant lymphoma. Radiother Oncol. 1998;49:233–243
  65. Dewit L, Anninga JK, Hoefnagel CA, Nooijen WJ. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys. 1990;19:977–983
  66. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implication for radiotherapy. Br J Cancer. 1955;9:539–549
  67. Brown JM. Evidence for acute hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol. 1979;52:650–656
  68. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol. 1991;20:13–19
  69. Gatenby RA, Kessler HB, Rosenblum JS. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831–838
  70. Hockel M, Schlengel K, Mitze M. Hypoxia and radiation response in human tumors. Sem Radiat Oncol. 1996;6:3–9
  71. Nordsmark M, Overgaard M, Overgaard J. Pretreatment ogygenation predicts radiation response in advanced quamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  72. Nordsmark M, Keller J, Hoyer M, Nielsen OS, Overgaard J. Hypoxia in human soft tissue sarcomas is associated with poor survival. Radiother Oncol. 1998;48:S162
  73. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Sem Radiat Oncol. 1996;6:10–21
  74. Kaanders JHAM, Pop LAM, Marres HAM. Accelerated radiotherapy with carbogen and nicotinamide (arcon) for laryngeal cancer. Radiother Oncol. 1998;48:115–122
  75. Battermann JJ, Breur K, Hart AAM, Van Peperzeel HA. Observations on pulmonary metastases in patients after single doses and multiple fractions of fast neutrons and Cobalt gamma rays. Eur J Cancer. 1981;17:539–545
  76. Bonnett DE, Blake SW, Shaw JE, Bewley DK. The Clatterbridge high energy neutron therapy facility: Specification and performance. Brit J Radiol. 1988;61:38–46
  77. Breteau N, Le Bourgeois JP, Battermann JJ, Wambersie A. High-LET particles in radiation therapy. Proc. of the EORTC workshop 1983. J Eur de Radiotherapie. 1984;5:115–248
  78. Cummings BJ, Keane TJ, Pintilie M. A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinomas of the larynx and pharynx. Radiother Oncol. 1996;40(I):S30
  79. Datta NR, Choudhry AD, Gupta S. Twice a day versus once a day radiation therapy in head and neck cancer (abstr.). Int J Radiat Oncol Biol Phys. 1989;17(I):132
  80. Horiot JC, Le Fur R, N’Guyen T. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231–241
  81. Pinto LHJ, Canary PCV, Araujo CMM, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991;21:557–562
  82. Sanchiz F, Milla A, Torner J. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1990;19:1347–1350
  83. Edsmyr F, Anderson L. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol. 1985;4:197–203
  84. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand?. Radiother Oncol. 1997;43:1–21
  85. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997;37:259–267
  86. Baumann M, Bentzen SM, Ang KK. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol. 1998;46:127–130
  87. Overgaard J, Hjelm-Hansen M, Vendelbo Johansen L, Andersen AP. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol. 1988;27:147–152
  88. Ang KK, Trotti A, Garden AS. Overall time factor in post-operative radiation: results of a prospective randomized trial. Radiother Oncol. 1996;40:S30
  89. Dische S, Saunders MI, Barrett A. A randomised mulicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  90. Saunders MI, Dische S, Barrett A. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomized multicentre trial. Lancet. 1997;350:161–165
  91. Horiot JC, Bontemps P, van den Bogaert W. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44:111–121
  92. Begg, A. C. Haustermans, K. Hart, A. A. M. et al., The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis.
  93. Macbeth F. An uncharted country. Clin Oncol. 1999;11:71–72
  94. Wilkinson JM, Hendry JH, Hunter RD. Dose rate consideration in the introduction of LDR afterloading intracavitary techniques for radiotherapy. Br J Radiol. 1980;53:890–893
  95. Stout R, Hunter RD, Mould RF. Clinical trials of changing dose rate in intracavitary low dose rate therapy. Brachytherapy 2. Netherlands: Nucletron International B.V., The; 1989; p. 219–222
  96. Newman G. Increased morbidity following the introduction of remote afterloading with increased dose rate, for cancer of the cervix. Radiother Oncol. 1996;39:97–103
  97. Rodrigues P, de Winter K, Venselaar J, Leer WH. Evaluation of late morbidity in patients with carcinoma of the uterine cervix following a dose rate change. Radiother Oncol. 1997;42:137–141
  98. Jones RD, Symonds RP, Habeshaw T. A comparison of remote afterloading and manually inserted caesium in the treatment of cancer of the cervix. Clin Oncol. 1990;2:193–198
  99. Patel FD. Dose rate correction in medium dose rate brachytherapy for carcinoma cervix. Radiother Oncol. 1998;49:317–323
  100. Hanks GE, Schultheiss TE, Hanlon AL. Optimization of conformal radiation treatment of prostate cancer: a report of a dose escalation study. Int J Radiat Oncol Biol Phys. 1997;37:543–550
  101. Zelefsky MJ, Leibel SA, Gaudin PB. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  102. Zelefsky MJ, Fuks Z, Wolfe T. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy – a dose-escalation study. Radiol. 1998;209:169–174
  103. Armstrong J, Raben A, Zelefsky M. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  104. Robertson JM, Ten Haken RK, Hazuka MB. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1079–1085
  105. Graham MV, Purdy JA, Emami B. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995;33:993–1000
  106. Fraass BA, McShan DL, Diaz RF. Integration of MRI into radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 1987;13:1897–1908
  107. De Neve V, de Wagter C, De Jaeger K. Planning and delivering high doses to targets surrounding the spinal cord at the lower neck and upper mediastinal levels: static beam-segmentation technique executed with a multileaf collimator. Radiother Oncol. 1996;40:271–279
  108. Lomax AJ, Bortfeld T, Goitein G. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol. 1999;51:257–271
  109. Bottrill DO, Plane JH, Newaishy GA. A proposed afterloading technique for irradiation of the esophagus. Br J Radiol. 1979;53:573–574
  110. Sutedja T, Baris G, Zoetmulder F. High dose rate brachytherapy improves resectability in squamous cell lung cancer. Chest. 1992;102:308–309
  111. Gaspar LE, Barnett R, Kocha WI. High dose rate esophageal brachytherapy: initial experience. Endocuriether Hypertherm Oncol. 1992;8L:5–10
  112. Sur RK, Singh DP, Sharma SC. Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1992;22:1043–1046
  113. McShan DL, Fraass BA. 3-D treatment planning: II. Integration of gray scale images and solid surface graphics. The Use of Computers In Radiation Therapy. 1987;41–44
  114. Goitein M, Abrahams M. Multi-dimensional treatment planning: I. Delineation of anatomy. Int J Radiat Oncol Biol Phys. 1983;9:777–787
  115. Goitein M, Abramd M, Rowell D, Pollari H and Wiles J. Mulit-dimensional treatment planning: II. Beam’s Eye View, back projection, and projection through Ct sections. Int J Radiat Oncol Biol Phys. 1983;9:789–797
  116. McShan DL, Fraas BA, Lichter AS. Full integration of the beam’s eye view concept into computerized treatment planning. Int J Radiat Oncol Biol Phys. 1990;15:481–495
  117. Barr GK, Kereiakes JG, Horwitz H. The method of linear programming applied to radiation treatment planning. Radiology. 1968;91:686–693
  118. Redpath AT, Vickery BL, Wright DH. A new technique for radiotherapy planning using quadratic programming. Phys Med Biol. 1967;21:781–791
  119. Webb S. Optimisation of conformal radiotherapy dose distributions by simulated annealing. Phys Med Biol. 1989;34:1349–1370
  120. Ling CC, Burman C, Chui C. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic mulileaf collimation. Int J Radiat Oncol Biol Phys. 1996;35:721–730
  121. Esik G, Bortfeld T, Bendel R, Nemeth G, Schiegel W. Inverse radiotherapy planning for a concave-convex PTV in cevical and upper mediastinal regions. Strahlenther Onkol. 1997;173:193–200
  122. De Wagter C, Colle CO, Fortan LG, Van Duyse BB, Van den Berge DL, De Neve WJ. 3D conformal intensity-modulated radiotherapy planning: interactive optimization by constrained matrix inversion. Radiother Oncol. 1998;47:69–76
  123. Redpath AT. Planning of beam intensity modulation using an advanced 3D dose calculation algorithm and a simulated annealing method. Radiother Oncol. 1998;49:295–304
  124. De Neve V, de Wagter C, De Jaeger K. Planning and delivering high doses to targets surrounding the spinal cord at the lower neck and upper mediastinal levels: static beam-segmentation technique executed with a multileaf collimator. Radiother Oncol. 1996;40:271–279
  125. Essers M, Lanson JH, Mijnheer B. In vivo dosimetry during conformal therapy of prostate cancer. Radiother Oncol. 1993;29:271–279
  126. Meertens H, van Herk M, Bijhold J, Bartelink H. First clinical experience with a newly developed electronic portal imaging device. Int J Radiat Oncol Biol Phys. 1990;18:1173–1181
  127. Dusserre A, Garavaglia G, Giraud JY, Bolla M. Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Radiother Oncol. 1995;36:229–234
  128. Van Tienhoven G, van Bree NAM, Mijnheer B, Bartelink H. Quality assurance of the EORTC trial 2281/10882. Assessment of the role of booster dose in breast conserving therapy: the dummy run. Radiother Oncol. 1991;22:290–298
  129. Valley JF, Bernier F, Tercier PA. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run. Radiother Oncol. 1998;37–44
  130. Deeley TJ. Radiotherapy for carcinoma of bronchus. Cancer Treatment Reviews. 1974;1:39–64
  131. Conformal radiotherapy for a nasopharygeal carcinoma showing the concave target volume around the spinal cord.

PII: S0305-7372(99)90141-X

doi: 10.1053/ctrv.1999.0141

Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 365-376 , December 1999

Article Tools